The Center for the Evaluation of Vaccination (CEV) of the University of Antwerp, headed by Prof. Pierre Van Damme, was founded in 1994. It has until present conducted more than 380 vaccine trials (phase 1-4) with a variety of vaccines and in all age groups. Furthermore, CEV has conducted more than 60 policy research projects related to vaccination. It has published more than 400 peer reviewed papers. The Center has been recognised by the World Health Organization as a WHO Collaborating Center for the control and prevention of viral hepatitis and more recently for the control and prevention of infectious diseases. CEV provides state-of-the-art infrastructure for the conduct of vaccine studies. The research mission of CEV is to improve knowledge on all aspects of vaccination and to support vaccination policy making.
Main roles in the project
The Center will provide support to all Phase I clinical trial preparatory activities to assess the safety, reactogenicity, tolerability and immunogenicity of the Traspain-based vaccine against T. cruzi. The Center will conduct the Phase I clinical trial including subject recruitment, vaccine administration, assessment of safety and tolerability and biological sampling for immune response. Furthermore, it will provide support for the analysis of clinical parameters and for the clinical study report.
Contact: Prof. Pierre Van Damme
This project has received funding from the European Union’s Horizon 2020 research and innovationprogramme under grant agreement No 815418.